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http://dx.doi.org/10.1016/j.blre.2017.02.001a b s t r a c ta r t i c l e i n f oAvailable online xxxx Themost commonly prescribed oral anticoagulantsworldwide are the vitaminK antagonists (VKAs) such aswar-
farin. Factors affecting the pharmacokinetics of VKAs are important because deviations from their narrow thera-
peutic window can result in bleedings due to over-anticoagulation or thrombosis because of under-
anticoagulation. In addition to pharmacodynamic interactions (e.g., augmented bleeding risk for concomitant
use of NSAIDs), interactions with drugs, foods, herbs, and over-the-countermedicationsmay affect the risk/ben-
eﬁt ratio of VKAs. Direct oral anticoagulants (DOACs) including Factor Xa inhibitors (rivaroxaban, apixaban and
edoxaban) and thrombin inhibitor (dabigatran) are poised to replace warfarin. Phase-3 studies and real-world
evaluations have established that the safety proﬁle of DOACs is superior to those of VKAs. However, some phar-
macokinetic and pharmacodynamic interactions are expected. Herein we present a critical review of VKAs and
DOACs with focus on their potential for interactions with drugs, foods, herbs and over-the-counter medications.
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Until recently, the vitamin K antagonists (VKAs) were the only oral an-
ticoagulant agents available, and warfarin remains the most commonly
prescribed oral anticoagulant worldwide. Its indications include a wide
range of clinical conditions from prevention of cardioembolic ischemic
stroke to deep venous thrombosis and pulmonary embolism. Anticoagu-
lants are used in patientswith a history of atrialﬁbrillation orﬂutter, recent
major surgery or immobility, heart valve replacement, ischemic stroke or
other thrombotic event [1]. Warfarin has signiﬁcant variability in dose-
response across individuals and a narrow therapeutic window (the inter-
national normalized ratio [PT-INR] value must remain between 2.0 and
3.0 for most indications) [2]. Clinical outcomes are highly correlated with
the amount of time patient's PT-INR values aremaintained in range [3]. Pa-
tients with an average individual time in therapeutic range N70% are con-
sidered to be at a low risk of a major hemorrhagic or thrombotic eventarmacologiche e Biomolecolari,
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Old and new oral anticoagula[4]. Frequentmonitoring of PT-INR lab values and dose adjustments, there-
fore, are necessary for safe and efﬁcacious use of warfarin [5]. Likewise, pa-
tient instruction and identiﬁcation of factors leading to over- or under-
anticoagulation are critical [6,7]. When combined with low-dose aspirin,
non-steroidal anti-inﬂammatory drugs (NSAIDs) or clopidogrel, warfarin
acts cumulatively, and risk of bleeding is signiﬁcantly increased [8,9].
VKAs are among the medications with the highest incidence of drug-
related life-threatening events [1] and top the list of interactions with
foods, herbal supplements, prescribeddrugs andover-the-countermedica-
tions [10,11]. Interactions resulting in over- or under-anticoagulation dras-
tically increase the risk of major hemorrhagic or thrombotic event.
Direct oral anticoagulants (DOACs), approved for the prevention and
treatment of venous thromboembolism and of systemic and cerebral
embolism in atrial ﬁbrillation [12], are poised to replace warfarin for
stroke prevention [13]. As their anticoagulant effect is more predictable
and stable (i.e., less inﬂuenced by interactions with foods, herbal sup-
plements, prescribed drugs and over-the-counter medications),
DOACs should prove safer and less problematic compared to the VKAs
[14]. Clinical studies of venous and arterial thromboprophylaxis suggest
that routine laboratory monitoring is not necessary with thrombin in-
hibitors or Factor Xa inhibitors. However, potential pharmacodynamic
interactions and drug interactions with foods, herbal supplements, pre-
scribed drugs and over-the-counter medications must still be consid-
ered with the use of DOACs [15].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The pharmacokinetic andpharmacodynamic effects onVKAs that re-
sult from interactions with foods, herbal supplements, prescribed drugs
and over-the-counter medications are summarized in Table 1, and de-
tailed in the Online Appendix. A variety of drugs, herbal medicines, nu-
trients that may affect dietary intake of Vitamin K may interact with
VKAs possibly changing their effect [16]. Mechanisms of such interac-
tions are herein discussed.
2.1. Drug-drug interactions affecting pharmacokinetic of warfarin
Several prescriptions and over-the-counter medications, foods and
herbal supplements alter the pharmacokinetics (absorption, distribu-
tion, metabolism and elimination) and pharmacodynamics (anticoagu-
lant effect) of warfarin (Table 1) [17,18].
The absorption of warfarin is reduced by concomitant use of
cholestyramine and sucralfate [19]. As warfarin is highly bound to
plasma proteins, other substances or medications that compete
for protein-binding sites (e.g., ibuprofen, quinidine, fenoﬁbrate,
losartan, valsartan, amlodipine, felodipine, sulﬁnpyrazone, phenyl-
butazone and the principal metabolite of chloral hydrate. i.e.
trichloracetic acid) displace warfarin, potentiating the anticoagu-
lant action of VKAs [20]. This effect, often observed as marginally
increased PT-INR, is typically transient and has a delayed onset
ranging from 1 day to 3 weeks (in the case of phenprocoumon)
after starting the concomitant drug regimen [21,22].
The majority of drug interactions affecting warfarin involves inhibi-
tion of the expression and/or activity of CYP450 enzymes involved in
warfarin metabolism (CYP2C9 for the S-enantiomer and CYPs 1A2,
2C19, 3A4 for R-enantiomer of warfarin). Interactions involving the S-
enantiomer may be of greater impact because the activity (anticoagu-
lant effect) of the S-enantiomer is 2 to 5-fold greater than that of theTable 1
Effect of commonly employed drugs on PT-INR [18,28].
Drugs that increase PT-INR Drugs that lower PT-INR
Drugs active on the central nervous system
Citaloprama Barbituratesa
Disulﬁram Carbamazepinea
Entacaponea Chlordiazepoxide
Phenytoin Propofol
Fluoxetine Ethanol
Propoxyphene
Fluvoxamine
Anti-inﬂammatory drugs
Acetaminophen Azathioprine
Allopurinol Mesalazine
Celecoxib Sulfasalazine
Dextropropoxyphene
Indomethacin
Interferon
Methyl-prednisolone
Phenylbutazone
Piroxicama
Sulindac
Sulﬁnpyrazone
Tramadol
Other
Cimetidinea Chelating agents
Omeprazole Cyclosporine
Orlistat Etretinate
CMF Anti-ﬂu vaccine
Danazol Menthol (anti-cough)
5-ﬂuorouracil Mercaptopurine
Ifosphamide Methimazole
Levamisole Multivitamin supplies
Levonorgestrel Raloxifene
Tamoxifen
Zileutona
a Clinically relevant interactions with warfarin.
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CYP2C9 (e.g., rifampin and phenobarbital) results in increased clearance
of warfarin and thus less anticoagulation [24].
Nearly 1 in 3 patients prescribed warfarin also prescribed a statin.
Several statins are metabolized by CYP3A4 and CYP2C9 isoenzymes.
Altered warfarin metabolism leading to increase PT-INR values has
been reported with concomitant use of ﬂuvastatin, lovastatin, simva-
statin or atorvastatin [25,26]. As the metabolism of pravastatin and
rosuvastatin does not involve CYP450 enzymes, potential for drug-
drug interactions with warfarin is limited [27,28]. Other cardiovas-
cular pharmacotherapies that interact with warfarin are listed in
Table 2.
HIV-positive patients often require anticoagulation therapy because
they are at increased risk of venous thromboembolismor cardiovascular
disease [29]. As several of the anti-retroviral agents (e.g., nevirapine,
efavirez, saquinavir and ritonavir) used to treat HIV interactwithwarfa-
rinmetabolismby inhibiting/inducingCYP enzymes (Table 3), clinicians
treating HIV-positive patients should be informed about the increased
likelihood of adverse reactions or decreased efﬁcacy of warfarin therapy
in this patient population [30,31,32,33].
Some of the anti-fungal drugs (e.g., ﬂuconazole, miconazole), and
antibiotics (e.g., azithromycin, ciproﬂoxacin) inhibit speciﬁc CYP450
iso-enzymes (Table 3), alteringwarfarin pharmacokinetics and increase
PT-INR values and risk of hemorrhage when combined with warfarin
[22,34]. In addition, they can also diminish gut absorption of Vitamin
K by altering the gut ﬂora. Although this is rarely of clinical signiﬁcance
(other than in malnourished patient populations), this altered ability to
absorb vitamin K can result in lowered synthesis of vitamin K-
dependent coagulation proteins and, ultimately, in an increased risk of
hemorrhage [35].
Several over-the-counter medications signiﬁcantly alter warfa-
rin metabolism. Increased PT-INR and pro-hemorrhagic effects
(e.g. ecchymosis, subcutaneous hematomas, hematuria) have
been reported after 2 weeks of concomitant use of over-the-
counter anti-fungal “Miconazole (oral gel)”, a strong CYP2C9 inhib-
itor, used for the treatment of oral Candidiasis [36]. Two case re-
ports of decreased PT-INR values with concomitant use of over-
the-counter menthol drops (antitussives) provide another exam-
ple of potential interactions between warfarin and over-the-
counter medications [37,38].
Drug-drug interactions may also affect warfarin elimination. For ex-
ample, the concomitant use of miconazole and phenylbutazone results
in increasedwarfarin elimination and decrease efﬁcacy ofwarfarin ther-
apy, by inhibiting the elimination of the S-enantiomer [16].Table 2
Cardiovascular drugs interfering with the metabolism/clearance of warfarin [28].
Drug [Reference(s)] Mechanism(s)
Drugs that increase PT-INR
Acetyl-salicylic acid Pharmacodynamics
Amiodaronea [24] Moderate inhibitor of CYP3A4, CYP1A2, CYP2C9
Dronedaronea [168,171] Moderate inhibitor of CYP3A4, inhibitor of P-gp
Atorvastatin [172] Inhibitor of CYP3A4
Quinidine [173] Inhibitor of CYP3A4
Cloﬁbratea [174] Inhibitor of CYP3A4
Diltiazema [28] Inhibitor of CYP3A4
Disopyramide [175] Inhibitor of CYP3A4
Fenoﬁbratea [172] Inhibitor of CYP3A4
Glucagon [176] Inhibitor of CYP3A4
Lovastatin [172] Inhibitor of CYP3A4
Propafenonea [177] Inhibitor of CYP3A4
Propranolola [178] Inhibitor of CYP1A2
Rosuvastatin [179] Inhibitor of CYP3A4
Simvastatin [25] Inhibitor of CYP3A4
Drugs that lower PT-INR
Cholestyramine [28] Interference with warfarin absorption
Telmisartan [180] Inhibitor of CYP3A4
a Clinically relevant interactions with warfarin.
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Table 3
Anti-infective drugs interfering with the metabolism/clearance of warfarin [28,181].
Drug [Reference(s)] Mechanism(s)
Amoxicillin, clavulanic acid
[102,103]
Reduced intrinsic vitamin K biosynthesis.
Azithromycin [182] Moderate inhibitor of CYP3A4, P-gp
Chloramphenicol [183] Inhibitor of CYP450
Ciproﬂoxacin [184] Strong inhibitor of CYP1A2
Clarithromycin [28] Moderate inhibitor of CYP3A4, P-gp
Sulfamethoxazole [185] Inhibitor of CYP3A4
Doxycycline [186] Inhibitor of CYP3A4
Efavirez [32] Moderate inhibitor of CYP2C19 and of
CYP3A4
Erithromycin [187] Moderate inhibitor of CYP3A4, P-gp
Fluconazole [188] Moderate inhibitor of CYP3A4, CYP1A2,
CYP2C9
Isoniazid [24] Inhibitor of CYP2C9
Itraconazole [28] Strong inhibitor of CYP3A4 e P-gp
Ketoconazole [28] Strong inhibitor of CYP3A4 e P-gp
Levoﬂoxacin [189] Inhibitor of CYP1A2
Metronidazole [190] Inhibitor of CYP1A2, CYP2C9
Miconazole gel [191] Inhibitor of CYP1A2, CYP2C9
Miconazole vaginal suppositories
[192]
Inhibitor of CYP1A2, CYP2C9
Nalidixic acid [24] Inhibitor of CYP1A2
Norﬂoxacin [185] Inhibitor of CYP3A4
Ritonavir [193] Strong inhibitor of CYP3A4, P-gp
Saquinavir [194] Inhibitor of CYP3A4
Tetracycline [24] Inhibitor of CYP3A4
Voriconazole [195] Strong inhibitor of CYP3A4, CYP1A2,
CYP2C9, P-gp
Griseofulvin [196] Inducer of warfarin-metabolizing enzymes
Ritonavir [193] Strong inducer of CYP2C19
Nafcillin [197] Strong inducer of CYP3A4
Nevirapine [33; 193] Strong inducer of CYP3A4
Rifampicin [24] Inducer of CYP3A4,CYP2C9
In bold, clinically relevant warfarin-drug interactions.
Table 4
Pharmacokinetic interaction of natural substances/foods with warfarin [20].
Natural substance Presence of inhibitor(s) of
Citrus bergamia CYP2C9
Carum Ajowan CYP3A4
Citrus aurantium (Orange) CYP3A4
Uncaria (Una de gato) CYP3A4
Vaccinium Myrtillus CYP2C9
Devil's clam CYP2C9
Dehydroepiandrosterone CYP3A4
Echinacea (purpurea and/or angustifolia) CYP3A4
Eucalyptus globulus CYP1A2, 2C9, 2C19, 3A4
Tanacetum parthenium CYP1A2, 2C9, 2C19, 3A4
Fo-ti-root CYP1A2, 2C9, 2C19, 3A4
Garlic CYP2C9, 2C19, 3A4
Hydrastis canadensis CYP3A4
Grape juice CYP1A2, 3A4
Ipriﬂavone CYP1A2, 2C9
Kava (Piper methysticum) CYP1A2, 2C9, 2C19, 3A4
Licorice CYP3A4
Lime CYP3A4
Wolfberries CYP2C9
Silybum marianum CYP2C9, 3A4
Peppermint CYP1A2, 2C9, 2C19, 3A4
Trifolium pratense CYP1A2, 2C9, 2C19, 3A4
Resveratrol CYP1A2, 3A4
Sulforaphane CYP1A2
Valeriana ofﬁcinalis CYP3A4
Prunus avium (wild cherry) CYP3A4
Natural substance Presence of inducer(s) of
3,3′-Diindolylmethane CYP1A2
Ginseng CYP1A2, 2C9, 2C19, 3A4
Guggul CYP3A4
Grapes (Vitis vinifera) CYP1A2
Indole-3-carbinol CYP1A2
Limonene CYP2C9
Hypericum perforatum CYP1A2, 2C9, 3A4
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Guidelines [1,4] recommend avoiding routine concomitant use of
warfarin and antiplatelet agents, with the exception of appropriate
therapeutic regimens in certain well identiﬁed clinical conditions [19,
39]. Medications affecting platelet function have a synergistic pharma-
codynamic interaction with warfarin; concomitant use, therefore, can
result in signiﬁcant increases in PT-INR and, in turn, in an increased
risk of bleeding [40,41,42].
Acetaminophen, a widely used over-the-counter analgesic and anti-
pyretic does not alter platelet function [43], but concomitant use of acet-
aminophen at doses ≥2 g/d for several days increases the
pharmacodynamic effect (increased PT-INR) of warfarin. Pharmacody-
namic drug interactions with warfarin are often of more clinical rele-
vance than those affecting only the pharmacokinetic of warfarin. Oral
contraceptives increase the risk of thrombosis by 4-5 folds compared
to placebo [44], and their use in patients prescribed warfarin must be
carefully assessed as they decrease protein S and increase the synthesis
of vitamin K dependent clotting factors [45].3. Foods and herbal medicines interactions with warfarin
3.1. Pharmacokinetic interactions of warfarin with food and herbal
medicines
Nearly 15% of the US population uses complementary and alternative
medicines (CAMs) in parallelwith conventional treatments [46]. Detailed
clinical information regarding various herbal supplements andmedicines
and their interactions with warfarin are summarized in Table 4. Unfortu-
nately, most patients receiving warfarin have poor knowledge about the
potential interactions of some CAMs and warfarin and seldom inform
their clinicians about their concomitant use of CAMs [47].Please cite this article as: Di Minno A, et al, Old and new oral anticoagula
http://dx.doi.org/10.1016/j.blre.2017.02.001One study of patients prescribed warfarin for chronic atrial ﬁbrilla-
tion found that about 50% were also taking an herbal supplement or
medication. Warfarin patients taking no herbal medications or only 1
herbal b4 times per weekweremore likely to have PT-INR values with-
in the optimal therapeutic range (2.0 to 3.0) compared to those
taking N 1 type of herbal ≥ 4 times per week (58.1% vs 51.1%, P =
0.046) [48]. Findings from several in vitro studies have shown that com-
ponents of herbal supplements may inhibit CYP2C9. This is seldom of
clinical signiﬁcance because these CYP2C9 components rarely achieve
appreciable intrahepatic concentrations [49]. In addition, no data have
been reported to date suggesting that foods or nutrients (other than
those containing Vitamin K) interact signiﬁcantly with warfarin
CYP2C9 metabolism [50,51].
The most important advice for patients is to maintain their usual
diet, since warfarin interactions with food have generally not clinical
implications when patients follow a stable diet [52]. Old recommenda-
tions for diets low in vitamin K should be considered obsolete [52].
3.1.1. Grapefruit
Components of grapefruit and grapefruit juice, mainly the furano-
coumarins, inhibit CYP3A4 activity [53,54]. However, only a few cases
of elevated PT-INR and/or minor hematomas have been reported [55].
Nonetheless, clinicians and patients should be aware of the potential in-
teraction between warfarin and grapefruit [54].
3.1.2. Green tea
Although green tea has several reported health beneﬁts [28], high
doses markedly reduce PT-INR. A change in PT-INR value from 3.8 to
1.4 has been reported, suggesting the potential for a signiﬁcant interac-
tion between green tea and VKAs when green tea is consumed in high
doses [48]. Moderate consumption of green tea, however, is not likely
to affect anticoagulant therapy because green tea contains minimalnts: Food, herbal medicines and drug interactions, Blood Rev (2017),
4 A. Di Minno et al. / Blood Reviews xxx (2017) xxx–xxxamount of Vitamin K [56,57] and the amounts of other compounds that
alter CYP activity, such as catechin and ﬂavonoids, are often insufﬁcient
to have an appreciable effect on PT-INR [58].
3.1.3. Chamomile (Matricaria chamomilla)
Chamomile, an herbal treatment for gastric discomfort, anxiety and
catarrh [59], in vitro inhibits CYP1A2 and, to a lesser extent, 3A4 and
2C9 [60]. A case of serious bleeding was observed in a 70-year old fe-
male patient on warfarin therapy who consumed large quantities of
chamomile [61].
3.1.4. Soybean or soy milk
Soybeans can be used to treat symptoms of menopause, osteoporo-
sis and hyperlipidemia [62]. Although in vitro soybean extracts inhibit
CYP3A4 and CYP2C9, they may also impair the anticoagulant activity
of warfarin [63,64] because they contain signiﬁcant amounts of Vitamin
K [65].
3.1.5. Mango
Mango contains high concentrations of retinol, a known inhibitor of
CYP2C19 [66]. Increases in PT-INR resulting from consuming even small
amounts of mango while receiving warfarin therapy can be clinically
relevant, and patients and clinicians need be aware of this potential in-
teraction [66,67].
3.1.6. Ginseng
Ginseng does not affect the pharmacokinetics or pharmacodynamics
of warfarin [68].
3.1.7. St. John's wort (Hypericum perforatum)
St. John's wort, often used to treat moderate depression, sleep disor-
ders, anxiety and pain [69,70], induces CYP1A2 [71], 2C9 [72,73] and
3A4 [74], resulting in increased clearance and reduction of plasma con-
centrations of warfarin. Long-term consumption of St. John's wort in-
creases the clearance of both the S (+29%, via CYP2C9) and the R
(+23%, via CYP3A4/CYP1A2) enantiomers of warfarin, resulting in a
clinically signiﬁcant reduction of the pharmacological effect of warfarin
[54,68].
3.1.8. Ginkgo biloba
Consumption of Ginkgo can increase the risk of bleeding in surgical
patients. Although one studywas unable to detect a difference inwarfa-
rin anticoagulation due to concomitant use of Ginkgo, in vitro studies
have shown that several ﬂavonol aglycones (e.g., amentoﬂavone)
found in Ginkgo are potent inhibitors of human CYP2C9 [75,76].
3.1.9. Cranberry (Vaccinium myrtillus)
Case-reports document increased PT-INR and incidence of hemor-
rhage attributed to the co-administration of cranberry juice (often
used in urinary infections) in patients on warfarin [77,78,79]. Cranberry
juice contains marginal amounts of Vitamin K [80,81] and ﬂavonoids'
oil. Although in vitro [82], animal [83] and small clinical studies [84,
85,86] suggest that cranberry juice alters CYP2C9 and 3A4 activity,mod-
erate daily consumption of cranberry juice (240–280 mL/d) has little
impact on PT-INR.
3.2. Pharmacodynamic interactions of foods and herbal supplements and
medicines with warfarin
Green, leafy vegetables and certain vegetable oils contain signiﬁcant
amounts Vitamin K, and their consumption in excess may result in de-
creased PT-INR. Conversely, decreased consumption or absorption (sec-
ondary to changes in gut ﬂora secondary to antibiotic use) of Vitamin K
and increased elimination (secondary to diarrhea) of Vitamin Kmay re-
sult in drastic increases in PT-INR and over anticoagulation [28].Please cite this article as: Di Minno A, et al, Old and new oral anticoagula
http://dx.doi.org/10.1016/j.blre.2017.02.001Likewise, biliary obstruction andmalabsorptionhave also been associat-
ed with decreased levels of Vitamin K and over-anticoagulation [22].
3.2.1. Ginkgo biloba
Ginkgolides, the major chemical components of Ginkgo biloba, have
anti-inﬂammatory and anti-platelet properties [87]. In a patient with
chronically stable PT-INR values on warfarin, intracranial hemorrhage
was reported after 2 months of concomitant use of Ginkgo biloba [88].
However, ﬁndings from two separate clinical trials reported that stan-
dardized extract of Ginkgo (240 mg/d/1 week or 100 mg/d/4 weeks)
does not alter the pharmacodynamic of warfarin [89]. Nevertheless,
routine monitoring of PT-INR is recommended for patients taking gink-
go in addition to warfarin [54].
3.2.2. Ginseng
Ginsenosides, the major active components of ginseng, inhibit
CYP1A2 [87], platelet aggregation and thromboxane formation [90,91].
The ﬁndings from three separate reports suggest that ginsengmarginal-
ly increases the anticoagulant effect of warfarin [90,92,93].
4. Interactions affecting pharmacokinetic or pharmacodynamics of
phenprocoumon and acenocumarol
In patients on chronic phenprocoumon, the increased risk of bleed-
ing of patients co-medicated with verapamil [59] and the increased
risk of thrombosis of patients co-medicated with carbamazepine [94]
suggest changes in phenprocoumon bioavailability aswell as speciﬁc ef-
fects on CYP450 enzymes playing a major role in themetabolism of this
VKA. Interactions between phenprocoumon and ambrisentan [95],
esomeprazole [96] and metformin [97] were also reported. In addition,
interactions with older macrolide antibiotics erythromycin and
clarithromycin, which inhibit CYP3A4, can trigger life-threatening hem-
orrhage and contribute to the incidence of medical drug-related hospi-
talizations [98]. Likewise, inhibition of CYP3A4-catalyzedmetabolism of
phenprocoumon by clarithromycin may result in an increase of both
bioavailability and risk of bleeding [99]. Avoidance of concomitant use
of co-trimoxazole with phenprocoumon (or acenocoumarol) is a safer
approach for the prevention of these potential interactions [100].
4.1. Phenprocoumon
A signiﬁcantly elevated risk of major bleeding has been observed for
drugs with known pharmacodynamic interactions with phenprocoumon
[101]. For instance, an increased risk of bleeding was reported with the
combined use of phenprocoumon and clopidogrel [101].
Antibiotics associated with an increased risk of hemorrhage in
phenprocoumon users include quinolones with ORs ranging from 2.74
(95% CI: 1.80–4.18) for ciproﬂoxacin to 4.40 (95% CI: 2.45–7.89) for
levoﬂoxacin, to 2.99 (95% CI: 1.39–6.42) for amoxicillin plus clavulanic
acid and to 3.57 (95% CI: 2.36–5.40) for cotrimoxazole [102,103].
Among NSAIDs, ketoprofen and naproxen were associated with the
highest risks [101]. Selective serotonin reuptake inhibitors (SSRIs),
such as citalopram, which inhibits the transport of serotonin into the
platelets, lead to impaired platelet function thus increasing the risk of
bleeding [104,105].
4.2. Acenocumarol
CYP2C9 polymorphisms have an impact on drug-drug interactions
during acenocoumarol treatment [106]. Case-reports and case-series
document interactions between acenocoumarol and levoﬂoxacin
[107], topical terbinaﬁne [108], amorolﬁne [109] or ciclopirox [110]. In-
creased PT-INR after acenocoumarol co-administration with geﬁtinib
[111] or with capecitabine [112] have also been reported. Phenytoin
and acenocoumarol share the same metabolizing pathway by hepatic
CYP2C9. The co-administration of therapeutic doses markedlynts: Food, herbal medicines and drug interactions, Blood Rev (2017),
5A. Di Minno et al. / Blood Reviews xxx (2017) xxx–xxxdecreases themetabolismof both drugs, leading to acute phenytoin tox-
icity and increased PT-INR, especially in individuals homozygous for
CYP2C9*3 [113].
Special emphasis has beendevoted to oral anticoagulation inHIV pa-
tients. Interaction between antiretroviral drugs (efavirenz and
atazanavir/ritonavir) with acenocoumarol has been documented to-
gether with the possibility of a safe concurrent use (i.e. the lack of inter-
action) of acenocoumarol with raltegravir [114]. Pulmonary arterial
hypertension is an uncommon although life-threatening complication
of HIV infection,which is treatedwith bosentan and oral anticoagulants.
However, because of its ability to induce the acenocoumarol metabo-
lism and, in turn, to increase PT-INR values, bosentan co-
administration with acenocoumarol (and other VKAs) requires a closer
PT-INRmonitoring not only during theﬁrstweeks of treatment, but also
during longer periods [115]. Sitaxentan is a conventional therapy for
pulmonary hypertension with/without HIV positivity. Sitaxentan in-
hibits the metabolism of acenocoumarol, resulting in a need for adjust-
ment of acenocoumarol dose when the two drugs are co-administered.
In a subset of patients enrolled in the STRIDE-3 study, a PT-INR ≥5 in at
least one determination was observed in 13 patients on long-term co-
treatment with acenocoumarol, although no a clinically signiﬁcant
bleeding event was recorded [116].
A potentiation of acenocoumarol-induced anticoagulation by co-
medication with omeprazole or esomeprazole and inhibition of
CYP2C19 were also reported [117]. The risk for over-anticoagulation
was most pronounced for esomeprazole (HR 1.99, 95% CI 1.55–2.55)
and lansoprazole (HR 1.49, 95% CI 1.05–2.10), whereas a non-
signiﬁcant risk increase for the other proton-pump inhibitors (PPIs)
was observed [117]. In the same report, no modiﬁcation of these ﬁnd-
ings was reported because of different CYP2C19*2 genotypes. Laryngeal
hematoma in relation to interaction between acenocoumarol and topi-
cal econazole lotion has also been reported because of drug-drug inter-
action affecting acenocoumarol elimination [118]. Finally, in addition to
red Ginseng (used for tiredness and dizziness), reduction of anticoagu-
lant therapy efﬁcacy (low PT-INR) with need to increase the dosage of
acenocoumarol was reported for a series of herbal medicines used for
weight loss [119].
A 15% decrease in acenocoumarol clearance (P b 0.05) when 1 g of
amoxicillin + 250 mg of clavulanic acid were co-administered has
been reported in healthy volunteers [120]. In contrast, co-
administration of sulfamethoxazole-trimethoprimwith acenocoumarol
increased by 3-fold the risk of over-anticoagulation. Clopidogrel andTable 5
Pharmacokinetic interactions of DOACs with drugs.
Direction of the change in plasma concent
column
Drug Inhibitor of Dabigatran [28] Rivaroxaba
Cyclosporine P-gp
Digoxin P-gp
Amiodarone P-gp
Dronedarone P-gp
Verapamil P-gp
Quinidine P-gp
Ritonavir P-gp and CYP3A4
Ketoconazole P-gp and CYP3A4
Itraconazole P-gp and CYP3A4
Voriconazole P-gp and CYP3A4
Posaconazole P-gp and CYP3A4
Azithromycin P-gp and CYP450
Erythromycin P-gp and CYP450
Clarithromycin P-gp and CYP450
Drug Inducer of
Rifampicin P-gp and CYP3A4
Phenytoin P-gp and CYP3A4
Carbamazepine P-gp and CYP3A4
Fenobarbital P-gp and CYP3A4
= increase in concentration; = reduction in concentration.
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5. Direct oral anticoagulant drugs (DOACs)
Comparative pharmacokinetics and pharmacodynamics of DOACs vs
warfarin are summarized in Online Table S1 and detailed in the Online
Appendix of this report.
5.1. Dabigatran
5.1.1. Drug-drug interactions affecting the pharmacokinetic of dabigatran
Pharmacokinetic interactions of DOACs with drugs are reported in
Table 5; relevant pharmacological interactions with dabigatran and
their clinical relevance are summarized in Table 6 and thosewith Factor
Xa inhibitors in Table 7.
Dabigatran etexilate, being not metabolized by cytochrome P450,
has low potential for clinically relevant interactionswith drugsmetabo-
lized by cytochrome P450 [122]. By contrast, this drug is a substrate for
P-glycoprotein 1 (P-gp) [123] and its co-administration with strong P-
gp inhibitors (e.g. ketoconazole and verapamil) or P-gp inducers (e.g. ri-
fampicin, St. John's wort, carbamazepine and phenytoin) should be
avoided [124]. No dose adjustment is needed with the concomitant
use of P-gp inhibitor amiodarone, whereas the usual dose 150 mg BID
should be reduced to 110 mg BID in patients receiving verapamil
[125]. Dronedarone should not be co-administered with dabigatran be-
cause it increases the levels of the later drug up to 2-fold [126]. Overall,
dabigatran etexilate should be given at least 2 h prior to co-
administering any P-gp inhibitor [127].
Atorvastatin (CYP3A4 substrate), diclofenac (CYP2C9 substrate)
or digoxin (P-gp inhibitor) have limited impact on dabigatran efﬁca-
cy, safety and tolerability [128]. Dabigatran absorption is reduced by
co-administration of anti-acids such as PPIs [129], even if this effect
is seldom of clinical relevance. Dabigatran bioavailability increases
after co-administration of ketoconazole [130] or quinidine [131]
and decreases after co-administration of rifampicin [132]. Hence,
these co-administrations should be avoided.
5.1.2. Drug-drug interactions affecting the pharmacodynamic of dabigatran
The co-administration of dabigatran with other anticoagulant/anti-
platelet drugs should be avoided and/or limited in time, unlessrations in response to coadministration of drugs reported in the ﬁrst
n [28,136] Apixaban [28,136] Edoxaban [149]
nts: Food, herbal medicines and drug interactions, Blood Rev (2017),
Table 6
Clinical use of dabigatran: relevant pharmacological interactions.
Drugs to be avoided Drugs to be used with caution Drugs of free use Drugs that enhance the effect Drugs that impair the effect
Carbamazepined
Cyclosporinec
Dronedaronec
Ketoconazolec
Phenytoind
Rifampicind
St. John's wortd
Verapamilc
Quinidinec
Quinine
Verapamilc
Amiodaronec
Atorvastatin (CYP3A4)
Clarithromycina,c
Diclofenac (CYP2C9)
Digoxin (P-gp)
Amiodarone
Dronedaronec
Ketoconazolea
Quinidine
Quinine
Verapamilc
Proton pump inhibitors
a Inhibitors of Cytochrome P450 iso-enzyme (CYP3A4).
b Inducers of Cytochrome P450 iso-enzyme (CYP3A4).
c Inhibitors of P-glycoprotein (P-gp).
d Inducers of P-glycoprotein (P-gp).
6 A. Di Minno et al. / Blood Reviews xxx (2017) xxx–xxxspeciﬁcally deﬁned. Co-administration with clopidogrel increases the
AUC and the Cmax of dabigatran of 30 and 40%, respectively [28]. In
addition, co-administration of dabigatran with aspirin (or diclofenac)
requires caution, because of the high risk of bleeding [19].
5.2. Rivaroxaban
5.2.1. Drug-drug interactions affecting the pharmacokinetic of rivaroxaban
Co-administration of rivaroxaban with the strong CYP3A4 inducer
rifampicin leads to≈50% decrease in mean AUC of Rivaroxaban [125].
Thus, decreases in rivaroxaban plasma concentrations are expected in
patients concomitantly treated with other strong CYP3A4 inducers
(e.g. phenytoin, carbamazepine, phenobarbital and St. John's wort).
Hence, caution is mandatory for such co-administrations.
By affecting its intestinal excretion, P-gp increases rivaroxaban plas-
ma concentrations [133]. Active substances, however, which strongly
inhibit only one of the elimination pathways, e.g. CYP3A4 or P-gp, in-
crease rivaroxaban concentrations only at a limited extent. For instance,
co-administration of the strong CYP3A4 inhibitor andmoderate P-gp in-
hibitor clarithromycin (or erythromycin) leads to small and clinically ir-
relevant increases inmean rivaroxaban AUC and Cmax [133]. In contrast,
co-administration of rivaroxaban with the strong CYP3A4 and P-gp in-
hibitors ketoconazole or ritonavir leads to a 2.6- and 2.5-fold increase
in mean rivaroxaban AUC and a 1.7- and 1.6-fold increase in mean
rivaroxaban Cmax, respectively, which translates into a higher thanTable 7
Clinical use of rivaroxaban, apixaban and edoxaban: relevant pharmacological interactions.
Drugs to be avoided Drugs to be
used with
caution
Drugs of free
use
Drugs
Amiodaronec
Chloramphenicola
Clarithromycina,c
Cyclosporinec
Dronedaronec
Itraconazolea
Ketoconazolea
Quinidinec
Quinine
Ritonavira
Verapamilc
Concomitant treatment with edoxaban is
also contraindicated in subjects receiving
erythromycin and azithromycin.
Carbamazepineb
Hypericum
perforatumd,b
Phenytoind,b
Rifampicind
Atorvastatin
Clarithromycin
Digoxin
Erythromycin
Fluconazole
Midazolam
Azithro
Clarith
Cyclosp
Diltiaz
Droned
Erythro
Itracon
Ketoco
Naprox
Quinid
Ritona
System
Verapa
The do
the dru
droned
No dos
amioda
a Inhibitors of Cytochrome P450 iso-enzyme (CYP3A4).
b Inducers of Cytochrome P450 iso-enzyme (CYP3A4).
c Inhibitors of P-glycoprotein (P-gp).
d Inducers of P-glycoprotein (P-gp).
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strong inhibitors of both CYP3A4 and P-gp is contraindicated.
5.2.2. Drug-drug interactions affecting the pharmacodynamic of
rivaroxaban
No signiﬁcant pharmacodynamic effects were reported when aspi-
rin [136] or clopidogrel [137] were co-administered with rivaroxaban.
In a study, however, clopidogrel does signiﬁcantly prolong (≈3-fold)
the mean bleeding time of subjects treated with Rivaroxaban [138].
Similarly, co-administration of 15 mg rivaroxaban with 500 mg
naproxen for two consecutive days was associated with a non-
clinically signiﬁcant prolongation of the bleeding time [139]. Finally, be-
cause of its additive effect, co-administration of rivaroxaban with other
anti-coagulant drugs (e.g. the anti Xa enoxaparin) is discouraged [28,
140].
5.3. Apixaban
5.3.1. Drug-drug interactions affecting the pharmacokinetic of apixaban
The concomitant use of apixaban with strong CYP3A4 and P-gp in-
ducers (e.g. phenytoin, carbamazepine, phenobarbital, rifampicin, or
St. John's wort) may lead to reduced apixaban plasma concentrations;
hence caution is mandatory when apixaban is co-administered with
strong CYP3A4 and P-gp inducers [141].that enhance the effect Drugs that impair the effect
mycin
romycin
orine
em
aronec
mycin
azole
nazole
en
ine
vir
ic Antifungals
mil
se of edoxaban should be halved when
g is co-administered with
arone, quinidine, or verapamil.
e adjustment is required for
rone.
Carbamazepine
Hypericum
Perforatum
Phenobarbital
Phenytoin
Rifampicin
Co-administration of apixaban with
rifampicin causes a signiﬁcant decrease in
mean AUC and Cmax of apixaban.
nts: Food, herbal medicines and drug interactions, Blood Rev (2017),
Table 8
Foods and herbal drugs that modulate P-gp activity [156].
Inhibitors [Reference(s)] Inducers [Reference(s)]
Humans Ginkgo biloba [198] St. John's wort [199]
Berberine [199]
Animal models Black pepper [200] Quercetin [199]
Grape juice [201] Scutellaria [199]
Apigenin [202] Soy milk and miso [203]
Rutin [202] Sucralose [204]
Capsaicin [205] Licorice root [199]
In vitro Lemonin [206] Genipin [207]
Soybean extract [208] Mango [209]
Notoginsenoside R1 [210]
Curcumin [211]
Green tea [212]
Fisetin [213]
Honokiol [213]
7A. Di Minno et al. / Blood Reviews xxx (2017) xxx–xxxApixaban is not recommended also in patients receiving concomi-
tant treatment with strong CYP3A4 or P-gp inhibitors, such as Ketoco-
nazole and ritonavir, which may increase dramatically its plasma
concentrations [142,143,144]. Diltiazem and other moderate CYP3A4
inhibitors as well as weak P-gp inhibitors lead to small increases in
mean apixaban AUC and Cmax and, in turn, to little effects on apixaban
pharmacokinetics. Naproxen an inhibitor of P-gp but not of CYP3A4,
leads to a 1.5- and 1.6-fold increase inmean apixaban AUC and Cmax, re-
spectively [145]. No dose adjustment is needed when apixaban is co-
administered with weak inhibitors of CYP3A4 and/or P-gp.
5.3.2. Drug-drug interactions affecting the pharmacodynamic of apixaban
In healthy volunteers or in patients with atrial ﬁbrillation [146], but
not in those with acute coronary syndromes [147], apixaban can be
safely combined with aspirin or clopidogrel. In contrast, co-
administration of naproxen and apixaban leads to an increased bioavail-
ability of this DOAC [148]. As for rivaroxaban, also the co-administration
of apixaban with low-molecular weight heparins is discouraged.
5.4. Edoxaban
5.4.1. Drug-drug interactions affecting the pharmacokinetic of edoxaban
Concomitant treatmentwith edoxaban is contraindicated in subjects
receiving ritonavir, cyclosporine, erythromycin, azithromycin,
clarithromycin, ketoconazole, itraconazole because these drugs increase
its steady-state plasma concentrations [149]. Edoxaban metabolism is
also largely affected by P-gp inhibitors or inducers. Edoxaban dose
should be halved when co-administered with P-gp inhibitors that in-
crease edoxaban exposure ≥1.5-fold (dronedarone: 84.5%; quinidine:
76.7%; verapamil: 52.7%) [150,151], whereas no dose adjustment is
needed when edoxaban is co-administered with amiodarone that in-
creases edoxaban exposure by only 40% [152].
5.4.2. Drug-drug interactions affecting the pharmacodynamic of edoxaban
In line with other DOACs, also edoxaban has major pharmacody-
namic interactions with antibiotics (clarithromycin, erythromycin, ri-
fampicin), anticoagulants (enoxaparin, warfarin), NSAIDs (ketoprofen,
naproxen) and platelet inhibitors (naproxen, clopidogrel, aspirin)
[153,154,155]. Pharmacodynamic interactions of edoxaban with low-
dose (100 mg) or high-dose (325 mg) of aspirin, or naproxen
(500 mg) administered to healthy subjects, seems not to be clinically
relevant [155]. In fact, although concomitant administration of
edoxaban with high-dose aspirin, low-dose aspirin, or naproxen in-
creases template bleeding times (BT) of approximately 2-fold, the ef-
fects of edoxaban on PT-INR, anti-FXa, and intrinsic FXa activity were
not inﬂuenced by either aspirin or naproxen. Moreover, inhibition of
platelet aggregation by high-dose aspirin, low-dose aspirin, or naproxen
is not affected by edoxaban [155].
6. Foods andherbalmedicines interactionswith pharmacokinetic or
pharmacodynamics of DOACs
No direct evidence is available regarding the inherent risk of co-
administration of food or herbal medicines with DOACs. St. John's
wort, a potent inducer of P-gp and CYP3A4, is expected to lower plasma
concentrations of dabigatran (substrate of P-gp) and of rivaroxaban or
apixaban (substrates of P-gp and CYP3A4). Such co-administration
should be made with caution with dabigatran and avoided with
rivaroxaban or Apixaban [124]. Although, in theory, food or herbal in-
hibitors/inducers of CYP3A4might interfere with the pharmacokinetics
of DOACs, no direct evidence of such interactions exists. Some food and
herbalmedicinesmodulate P-gp in vitro (Table 8) [156] but no informa-
tion is available whether these substances interact with DOACs. Finally,
to the best of our knowledge, no information is available concerning
pharmacodynamic interactions of DOACs with foods or herbal
medicines.Please cite this article as: Di Minno A, et al, Old and new oral anticoagula
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7.1. Warfarin
Due to its complexmulti-stepmetabolism, the largemajority ofwar-
farin interactions are mediated by CYP2C9, 1A2, 2C19 and 3A4 isoen-
zymes. Inhibitors and inducers of these enzymes do affect the
pharmacological activity of warfarin and, in turn PT-INR values. In
most cases adverse drug reactions due to these interactions lead to
bleeding events that may be severe, life-threatening and even fatal.
There is no convincing evidence to indicate that any food or nutrient
(other than Vitamin K) interacts signiﬁcantly with warfarin through
modulation of CYP2C9 activity [50,51].
Herbal medicines that inhibit CYP2C9 in vitrowould not be clinically
important unless the inhibitor reaches the liver in sufﬁcient concentra-
tions to inhibit the enzyme in vivo. The discrepancy between in vitro
[75] and in vivo [76] effects of the potent inhibitors of human CYP2C9
ﬂavonol aglycones clearly elucidates this concept.
Drug interactions involving CYP2C9, CYP1A2 and CYP3A4 isozymes
are usually delayed. The effect of the interaction will not be observed
until the interacting agent has reached a steady state (about 5 half-
lives of the interacting agent) [157]. Additionally, given the indirect
mechanismof the effect ofwarfarin, clotting factors present in the circu-
lation should be depleted prior to detecting the effect of the interacting
agent. This will take several days. Together, the onset and the offset of
the interaction (i.e. the effect on the PT-INR) is observed within 3 to
5 days for interacting substances with short half-lives and at longer
time intervals for drugs with longer half-lives. All in all, depending on
the interacting agent employed, the full impact of steady-state interac-
tions may not be apparent for-2 to 3 weeks. Likewise, a-wash-out peri-
od of several weeks may be needed before normalization of the hepatic
enzymes, when the inducer is discontinued.
Genetic polymorphisms of the CYP2C9 and of the Vitamin K epoxide
reductase complex subunit 1 (VKORC1, see Online Appendix) enzymes
have a strong impact on drug interactions and, in turn, the responsive-
ness of warfarin [158]. Individuals with polymorphisms that reduce
the expression of functional CYP2C9 will appear to be “warfarin sensi-
tive,” in that usual warfarin doses cause excessive anticoagulation
[159]. The 2C9*3 variant (Ile359Leu) shows an 80% loss of enzymatic ac-
tivity in vitro, whereas the CYP2C9*2 variant (Arg144Cys) reduces the
activity by≈30%. Under these conditions, decreased clearance and in-
creased in vivo anticoagulant effect have been shown [160]. The inter-
individual variation due to the CYP2C9 genotype appears to be compa-
rable to that related to a major non-genetic factor e.g. patient age [161].
Age, bodyweight, body surface area, sex, antibiotics that alter the in-
testinal environment, disease conditions and dietary intake of VitaminK
affect the responsiveness to warfarin as much as genetic polymor-
phisms [162,163]. In patients with signiﬁcant medical illness requiringnts: Food, herbal medicines and drug interactions, Blood Rev (2017),
8 A. Di Minno et al. / Blood Reviews xxx (2017) xxx–xxxmultiple medications and having a poor nutritional status, the ability to
isolate the impact of a particularmedication on thepatient's coagulation
status is difﬁcult. Broad-spectrum antibiotics are postulated to potenti-
atewarfarin by altering the normal intestinal ﬂora, thereby reducing the
body's ability to synthesize Vitamin K. However, this factor is unlikely to
be clinically signiﬁcant for most patients, except those who are mal-
nourished or havemalabsorption [164]. In addition to albumin,warfarin
is highly bound to a variety of plasma proteins and has the potential for
interacting with other highly protein-bound substances. However, the
effect of such interactions is usually transient and its clinical signiﬁcance
questionable [22].
Pharmacodynamic drug interactions with warfarin are more clini-
cally relevant than thosewith foods and drugs. Anymedication that im-
pairs the ability of platelets to function (e.g., acetylsalicylic acid,
clopidogrel, NSAIDs) and is given concomitantly with warfarin may in-
crease the risk of bleeding without affecting the PT-INR. Aspirin and
NSAIDs behave like this [41]. Conversely, medications such as estrogens
increase the risk of thrombosis and their use in patients who are taking
warfarin should be carefully assessed [44].
7.2. DOACs
Large-scale phase 3 studies [14], and real-world evaluations have def-
initely established that the use of DOACs iswell tolerated (as compared to
warfarin), and that adverse reactions (including intra-cerebral bleeding)
are quantitatively and qualitatively less relevant than thosewithwarfarin
from a clinical standpoint [165,166]. Thus, the use of DOACs is likely to
grow as more data become available regarding their long-term use and
their use in speciﬁc patients' populations.
Pharmacokinetics of Factor Xa inhibitors may be affected by the co-
administration of inducers/inhibitors of CYP3A4 and/or P-gp [133,167,
168]. In particular, potent inhibitors of CYP3A4 and of P-gp (e.g. ketoco-
nazole - antifungal drug - or protease inhibitors of HIV) should be
avoided [169]. Caution is also suggested for the co-administration of po-
tent inducers of CYP3A4 and of P-gp (e.g. carbamazepine, phenytoin)
[170].
Being able to affect circulating levels of the anticoagulant drug,
strong inhibitors/inducers of P-gp should not be co-administered with
dabigatran, a speciﬁc substrate for P-gp.
Little information is so far available as to the interaction of DOACs
with food, most herbal medicines or over-the-counter medications.
Since some herbal drugs and over-the-counter medications modulate
P-gp activity (Table 8), their ability to affect the anticoagulant potential
of DOACs should be thoroughly analyzed. However, while ad hoc phase
IV studies are needed in this area, a limited clinical impact of such herbal
drugs and over-the-counter medications to affect DOACs effects is pre-
dicted [165,166].
8. Practice points
• Multiple pharmacokinetic and pharmacodynamic interactions with
food, herbs, over-the-counter and other drugs can inﬂuence efﬁcacy
and safety of both vitamin K antagonists (VKAs) and direct oral anti-
coagulants (DOACs).
• Bleeding disorders associated to VKAs-interactions have been often
described as severe, life-threatening and even fatal, whereas those as-
sociated to DOACs-interactions appear to be less relevant.
• VKAs interactions have been widely investigated; those involving
DOACs were much less studied.
Research agenda
The safety proﬁle of DOACswith a speciﬁc focus on their interactions
with foods, herbs and/or over-the-counter medications needs further
assessments.Please cite this article as: Di Minno A, et al, Old and new oral anticoagula
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